Ricklie Julian is an Oncology physician affiliated with University of Arizona. OpenAlex indexes 49 publications with 541 citations (h-index 12); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3838 N Campbell Ave
Tucson, AZ 857191454
Telephone
520-694-2873Provider last certified this registry record 12 Dec 2024.
Clinical trials
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Sponsor: University of Arizona
- Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
Sponsor: University of Arizona
- Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Sponsor: University of Arizona
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AtriCure, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
34.5%l-Thyroxine34.5%Levothyroxine Sodium93%Synthroid7%Part D<11 patientsNervous system
25.3%Opioid Agonist11.3%Oxycodone Hcl78%Tramadol Hcl22%Part D<11 patientsPhenothiazine8.8%Prochlorperazine Maleate100%Part D≥27 patients+ 1 more class in this area
Cardiovascular
10.4%Antiarrhythmic7%Lidocaine-Prilocaine58%Lidocaine Hcl Viscous42%Part D<11 patientsCalcium channel blocker3.4%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
Journal for ImmunoTherapy of Cancer
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Alison Stopeck, MD
University of Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”